Cary Street Partners Investment Advisory’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,000	Closed	-$21K	–	1809
2023 Q1	$21K	Hold	5,000	–	–	﹤0.01%	959
2022 Q4	$30.1K	Buy	+5,000	New	+$27.3K	﹤0.01%	864

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Cary Street Partners Investment Advisory's CTIC Position: Q2 2023 in Review

Cary Street Partners Investment Advisory sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 5,000 shares — an estimated $21K sold.

Cary Street Partners Investment Advisory first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $30.1K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Cary Street Partners Investment Advisory reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 5,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $21K.
Cary Street Partners Investment Advisory first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Cary Street Partners Investment Advisory's CTI BioPharma Corp. (DE) Common Stock position peaked at $30.1K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2023, filed 10 Aug 2023.